Accuray Incorporated designs, develops and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa and the rest of the Asia Pacific region. The company is headquartered in Sunnyvale, California.
| Revenue (TTM) | $428.57M |
| Gross Profit (TTM) | $115.36M |
| EBITDA | $-5.59M |
| Operating Margin | -2.43% |
| Return on Equity | -101.10% |
| Return on Assets | -1.65% |
| Revenue/Share (TTM) | $3.64 |
| Book Value | $0.35 |
| Price-to-Book | 0.78 |
| Price-to-Sales (TTM) | 0.07 |
| EV/Revenue | 0.413 |
| EV/EBITDA | 26.28 |
| Quarterly Earnings Growth (YoY) | -96.20% |
| Quarterly Revenue Growth (YoY) | -7.40% |
| Shares Outstanding | $118.96M |
| Float | $113.06M |
| % Insiders | 4.35% |
| % Institutions | 69.16% |
MADISON, Wis., May 29, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Paul Miele, the company's new Chief Commercial Officer and David Shin, the company's new Chief Legal Officer.
MADISON, Wis., May 15, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced a new 10‑year strategic collaboration to advance personalized cancer treatments using Accuray's Stellar™ adaptive radiation therapy platform.
Accuray Incorporated (ARAY) Q3 2026 Earnings Call Transcript
MADISON, Wis., May 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter ended March 31, 2026.
MADISON, Wis., April 22, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2026, ended March 31, 2026, during a conference call hosted by company management at 1:30 p.m.
